New treatment perspectives in autism spectrum disorders [E-Book] / Roberto Canitano ; Yuri Bozzi
Lausanne : Frontiers Media SA, 2015
1 electronic resource (161 pages)
englisch
9782889195305
neurodevelopmental disorder ; autism ; Clinical Trial ; mouse model ; Genetics
Full Text
LEADER 03168nam a2200277uu 4500
001 17826
008 170415s|||| xx o 0 u ||| |
020 |a 9782889195305 
035 |a (Sirsi) a660709 
035 |a a660709 
041 |a eng 
245 1 0 |a New treatment perspectives in autism spectrum disorders  |h [E-Book] /  |c Roberto Canitano ; Yuri Bozzi 
264 1 |a Lausanne :  |b Frontiers Media SA,  |c 2015  |e (DOAB) 
300 |a 1 electronic resource (161 pages) 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a englisch 
520 |a Developing novel and more effective treatments that improve quality of life for individuals with autism spectrum disorders is urgently needed. To date a wide range of behavioral interventions have been shown to be safe and effective for improving language and cognition and adaptive behavior in children and adolescents with ASD. However many people with ASD can receive additional benefit from targeted pharmacological interventions. One of the major drawback in setting up therapeutics intervention is the remarkable individual differences found across individuals with ASD. As a matter of fact the medications that are currently available address only symptoms associated with ASD and not the core domains of social and communication dysfunction. The pathogenesis paradigm shift of ASD towards synaptic abnormalities moved the research to pathway to disease that involve multiple systems and that are becoming the forefront of ASD treatment and are pointing toward the development of new targeted treatments. Some new therapeutics have been tested and others are being studied. In this context single gene disorders frequently associated with ASD such as Rett Syndrome, Fragile X and Tuberous Sclerosis have been of significant aid as neurobiology of these disorders is more clear and has a potential to shed light on the altered signaling in ASD. However much research is needed to further understand the basic mechanisms of disease and the relationship to idiopathic ASD. Clinical trials in children are underway with agents directed to core symptoms and to the associated disorders in the search of new therapeutics and progress are expected with possible new option for therapeutics in ASD in the upcoming future. Children and Adolescents with ASD and their families can provide important information about their experience with new treatments and this should be a priority for future research. In addition, research performed on genetic mouse models of ASD will keep on providing useful information on the molecular pathways disrupted in the disease, thus contributing to identify novel drug targets. 
650 0 |a Pediatrics 
650 0 |a Medicine (General) 
653 |a neurodevelopmental disorder ; autism ; Clinical Trial ; mouse model ; Genetics 
856 |u http://journal.frontiersin.org/researchtopic/2032/new-treatment-perspectives-in-autism-spectrum-disorders  |z Volltext 
915 |a zzwFZJFrontiers 
596 |a 1 
949 |a XX(660709.1)  |w AUTO  |c 1  |i 660709-1001  |l ELECTRONIC  |m ZB  |r N  |s Y  |t E-BOOK  |u 15/5/2017  |x UNKNOWN  |z UNKNOWN  |1 ONLINE